Group 1 - The core point of the news is that Asia-Pacific Pharmaceutical experienced a significant stock price increase, reaching a limit up of 9.96% on August 1, with a trading price of 7.36 yuan per share and a total market capitalization of 5.488 billion yuan [1] - The company is located in Shaoxing, Zhejiang Province, and operates as a comprehensive pharmaceutical enterprise engaged in research, production, and sales, with a product range that includes chemical drug formulations, raw materials, and drug development [1] - Asia-Pacific Pharmaceutical holds 106 drug approval numbers and over 20 technology patents, having passed the national GMP certification, with products distributed across multiple provinces in China and exported overseas [1] Group 2 - As of March 31, the number of shareholders for Asia-Pacific Pharmaceutical was 60,800, with an average of 12,200 circulating shares per person [2] - For the first quarter of 2025, the company reported operating revenue of 64.55 million yuan, a year-on-year decrease of 42.73%, and a net profit attributable to shareholders of -7.80 million yuan, reflecting a year-on-year decrease of 160.25% [2]

龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%、日换手率达20%、日涨幅偏离值 达7%上榜龙虎榜3次，买卖居前营业部中，机构净卖出3720.35万元，营业部席位合计净卖出5355.28万 元。 4月30日公司发布的一季报数据显示，一季度公司共实现营业总收入0.65亿元，同比下降42.73%，实现 净利润-780.32万元，同比下降160.25%。7月15日公司公布了上半年业绩预告，预计实现净利润1.00亿元 至1.10亿元，同比变动区间为1726.42%~1909.06%。（数据宝） 亚太药业再度涨停，5个交易日内录得3个涨停，累计涨幅为31.44%，累计换手率为168.04%。截至 13:33，该股今日成交量2.64亿股，成交金额18.68亿元，换手率35.39%。最新A股总市值达55.18亿元。 证券时报·数据宝统计，两融数据来看，该股最新（7月31日）两融余额为1.84亿元，其中，融资余额 1.84亿元，较前一个交易日减少3460.68万元，环比下降15.80%，近5日累计减少5188.35万元，环比下降 21.96%。 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流 ...

7月31日，上证指数下跌1.18%，深证成指下跌1.73%，创业板指下跌1.66%。盘后龙虎榜数据显示，共 有50只个股因当日异动登上龙虎榜，资金净流入最多的是诺德股份（600110.SH），达4.23亿元。 据21投资通智能监测，26只个股龙虎榜出现了机构的身影，北向资金参与龙虎榜中的个股共涉及16只。 4.23亿资金抢筹诺德股份，1.98亿资金出逃亚太药业 50只上榜的龙虎榜个股中，31只个股被净买入，19只个股被净卖出。其中，资金净买入最多的是诺德股 份，达4.23亿元，占总成交金额的22.01%。诺德股份当日收盘上涨10.02%，换手率为17.98%。 而龙虎榜中资金净流出最多的是亚太药业（002370.SZ），被净卖出为1.98亿元，占总成交金额的 10.06%。亚太药业收盘下跌6.14%，换手率为37.4%。 机构净卖出的个股中，金额最多的是东芯股份（688110.SH），当日收盘上涨19.99%，换手率为 7.22%。 北向资金净买入11股，净卖出5股 7月31日，北向资金参与龙虎榜中的个股共有16只，合计净买入7.96亿元。其中沪股通净买入6 股，净卖 出2 股，合计净买入6.2亿元；深股通净 ...

Core Viewpoint - Asia Pacific Pharmaceutical experienced a decline of 6.14% in stock price, with a turnover rate of 37.40% and a trading volume of 1.966 billion yuan, indicating significant market activity and volatility [2] Trading Activity - The stock was listed on the Dragon and Tiger list due to its turnover rate reaching 37.40%, with institutional investors net buying 15.3086 million yuan [2] - The top five trading departments accounted for a total transaction volume of 470 million yuan, with a net selling amount of 198 million yuan [2] - Among the trading departments, one institutional seat was noted, with a net buy of 15.3086 million yuan after buying 19.6032 million yuan and selling 4.2945 million yuan [2] Recent Performance - Over the past six months, the stock has appeared on the Dragon and Tiger list six times, with an average price increase of 4.65% the day after being listed and an average increase of 11.43% in the following five days [3] - Today, the stock saw a net outflow of 45.2933 million yuan in main funds, with large orders contributing to a net outflow of 21.4823 million yuan and 23.8110 million yuan respectively [3] - In the last five days, the main funds experienced a net inflow of 186 million yuan [3]

Group 1 - Asia-Pacific Pharmaceutical (002370.SZ) experienced a decline of 6.14% today, with a turnover rate of 37.4% and a transaction volume of 1.966 billion yuan [1] - The top selling seat was "Hujialou" with a net sell of 173 million yuan, while "Quantitative Fund" ranked third with a net sell of 14.54 million yuan [1] - The total buying amount from the top buying seats was 1.36 billion yuan, while the total selling amount was 3.34 billion yuan, resulting in a net sell of 198 million yuan [1] Group 2 - The top five buying firms accounted for a total buying amount of 136.37 million yuan, representing 6.94% of total transactions [1] - The top five selling firms had a total selling amount of 334.11 million yuan, which is 16.99% of total transactions [1] - The net amount from the top five buying and selling firms combined was -197.73 million yuan [1]

| 买入金额最大的前5名 | | | | | | | --- | --- | --- | --- | --- | --- | | 序号 | 交易营业部名称 | | | 买入金额(万) | 占总成交比例 | | 1 | 国信证券股份有限公司浙江互联网分公司 | 255次 29.80% | 2 | 2179.40 | 1.11% | | 2 | 机构专用 | 1414次 43.42% | A | 1960.32 | 1.00% | | 3 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | 854次 31.62% | A | 1867.54 | 0.95% | | 4 | 中信证券股份有限公司浙江分公司 | 152次 31.58% | A | 1679.03 | 0.85% | | 5 | 东方财富证券股份有限公司拉萨金融城南环路证券营业部 | 748次 31.55% | > | 1549.07 | 0.79% | | | 卖出金额最大的前5名 | | | | | | 序号 | 交易营业部名称 | | | 买入金额(万) | 占总成交比例 | | 1 | 中信建投证券股份有限公司北京东城分公司 | 16次 ...

Core Viewpoint - The stock price of Asia-Pacific Pharmaceutical has significantly increased due to the rise in the innovative drug sector, with a year-to-date increase of 135% as of July 30, closing at 7.17 yuan per share [2][5]. Company Performance - Asia-Pacific Pharmaceutical expects to achieve a net profit attributable to shareholders of 100 million to 110 million yuan in the first half of 2025, representing a year-on-year growth of 1726.42% to 1909.06% [2][4]. - The company has faced financial challenges in recent years, with revenues of 515 million yuan in 2020, 315 million yuan in 2021, 373 million yuan in 2022, and 421 million yuan in 2023, alongside net profits of 27.27 million yuan, -228 million yuan, -133 million yuan, and -11.87 million yuan respectively [3]. - In 2024, the company reported revenues of 405 million yuan, a decrease of 3.68% year-on-year, but turned a profit with a net profit of 34.24 million yuan, primarily due to non-recurring gains [3][4]. Business Operations - Asia-Pacific Pharmaceutical specializes in the research, production, and sales of chemical preparations, with a portfolio of 111 approved formulations and five raw material drug approvals [3]. - The company has been actively restructuring, including the sale of its subsidiary, which contributed approximately 149 million yuan to its profit total for the first half of 2025 [4]. Industry Context - The innovative drug index has surged nearly 50% since the beginning of 2025, reflecting a broader trend in the industry driven by policy benefits, technological breakthroughs, and increased capital inflow [7]. - The Chinese innovative drug sector is transitioning from "generic" to "global innovation," with a significant increase in licensing transactions and contributions to international conferences [8].

证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交4.35亿元，其中，买入成交额为1.84亿 元，卖出成交额为2.52亿元，合计净卖出6788.88万元。 具体来看，今日上榜的营业部中，共有2家机构专用席位现身，即卖二、卖五，合计买入金额1420.50万 元，卖出金额7335.01万元，合计净卖出5914.52万元。 近半年该股累计上榜龙虎榜5次，上榜次日股价平均涨7.35%，上榜后5日平均涨19.39%。 亚太药业今日上涨5.29%，全天换手率43.73%，成交额23.71亿元，振幅6.70%。龙虎榜数据显示，机构 净卖出5914.52万元，营业部席位合计净卖出874.37万元。 深交所公开信息显示，当日该股因日换手率达43.73%上榜，机构专用席位净卖出5914.52万元。 亚太药业7月30日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 中信建投证券股份有限公司北京东城分公司 | 7660.22 | 7615.96 | | 买二 | 中国国际金融股份有限公司上海 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司有驱蚊或者防蚊产品吗？ 亚太药业（002370.SZ）7月30日在投资者互动平台表示，公司无相关产品。 ...

New Stock Listings - HanGao Group listed on July 30, 2025, with an issue price of 15.43[1] - *ST Zitian and *ST Suwu are under severe abnormal fluctuations as of July 30, 2025[1] - Tianlu Convertible Bonds listed on July 30, 2025, with a risk warning[1] Market Alerts - Multiple stocks including *ST Xinchao and *ST Yuancheng are flagged for severe abnormal fluctuations on July 30, 2025[1] - New listings include companies like Xianghe Precision and Shenshui Planning, with announcements made on July 30, 2025[1] - The report includes links to detailed announcements for each stock, ensuring transparency and accessibility for investors[1] Trading Insights - The report highlights the importance of monitoring newly listed stocks for potential volatility and investment opportunities[1] - Investors are advised to review the latest announcements and risk warnings associated with these stocks to make informed decisions[1]